AMANDA MURPHY
Associate Director, Investor Relations & Public Relations, Aegerion Pharmaceuticals
Email: amanda.murphy@aegerion.com
Phone: 857-242-5024
Company Reports Preliminary Total Net Product Sales Expected to be Between $150 million and $152 million, Exceeding High End of Prior Guidance
Global Expansion Plans for Metreleptin Opportunity Underway
If approved, metreleptin would be the first medication available in the EU to treat generalized and partial lipodystrophies
More than 100 patients are currently treated with metreleptin via a compassionate use program in Europe
Vancouver, BC, December 16, 2016 - Novelion Therapeutics (NASDAQ: NVLN) (TSX: NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first commercial shipment of JUXTAPID® (lomitapide) to a patient in Japan. In September 2016, JUXTAPID was approved by Japan’s Ministry of Health, Labor & Welfare (MHLW) for patients with homozygous familial hypercholesterolemia (HoFH).
